Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort
Oluwadunni E. Emiloju, Jun Yin, Emily J. Koubek, Joel M. Reid, Mitesh J. Borad, Yanyan Lou, Mahesh Seetharam, Martin J. Edelman, Edward A. Sausville, Yixing Jiang, Ahmed O. Kaseb, James Posey, S. Lindsey Davis, Gregory J. Gores, Lewis R. Roberts, Naoko Takebe, Gary K. Schwartz, Andrea E. Wahner Hendrickson, Scott H. Kaufmann, Alex A. Adjei, Joleen M. Hubbard, Brian A. Costello
Topics & Concepts
SorafenibHepatocellular carcinomaMedicineCohortInternal medicineRefractory (planetary science)OncologyPharmacologyGastroenterologyBiologyAstrobiologyHepatocellular Carcinoma Treatment and PrognosisCell death mechanisms and regulationPancreatic and Hepatic Oncology Research